Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.

Rhea-AI Summary

Therapeutic Solutions International (TSOI) has announced the formation of a spin-off company, Res Nova Bio, Inc., focusing on developing the StemVacs-V anti-angiogenesis immunotherapy for breast cancer. This innovative therapy utilizes induced pluripotent stem cells (iPSCs) to create a therapeutic vaccine that targets tumor blood vessels, promoting immune response. The technology is expected to enhance treatment efficacy, capitalizing on past successes with similar therapies. TSOI positions itself as a hub of innovation, aiming for accelerated development through this strategic spin-off.

Positive

• Formation of Res Nova Bio, Inc. to focus on StemVacs-V immunotherapy.
• StemVacs-V utilizes iPSCs for creating new cells, enhancing treatment standardization.
• Potential to target tumor blood vessels effectively, with a significant kill ratio of tumor cells.

Negative

• None.

Company to Develop StemVacs-V Anti-Angiogenesis Immunotherapy for Initial Treatment of Breast Cancer

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today formation of a Spin-Off Company, Res Nova Bio, Inc., dedicated to the development of cancer inhibiting anti-angiogenesis immunotherapies.

Res Nova Bio has licensed from Therapeutic Solutions International intellectual property covering StemVacs-V which is an iPSC derived platform technology announced in May of 2021¹ and discussed with potential corporate partners in September 2021².

The technology utilizes pluripotent stem cells called iPSCs in order to generate new cells which resemble tumor blood vessels that are made to act as a “therapeutic vaccine”. Specifically, the administration of StemVacs-V stimulates the immune system to selectively kill blood vessels that feed the tumor but not healthy blood vessels. It is believed that for every 1 tumor blood vessel cell that is killed, 200-300 tumor cells are also killed as a result.

“I have previously been involved in the original studies using placental cells to stimulate immunity to cancer endothelium (blood vessels), using a product called “ValloVax”. Having administered ValloVax to cancer patients I have seen the potency of this product firsthand. Unfortunately, despite receiving FDA clearance, commercial development of ValloVax ceased, therefore, in collaboration with scientists at Therapeutic Solutions International we developed a second generation ValloVax called StemVacs-V,” said Dr. James Veltmeyer, co-inventor and Chief Medical Officer of Therapeutic Solutions International. “In contrast to previous approaches, StemVacs-V allows for creating all doses from one standardized cell type, which alleviates the need for multiple placentas, avoiding variability in production. Additionally, because StemVacs-V is derived from iPSC, gene editing can be performed in order to increase therapeutic efficacy.”

“Therapeutic Solutions International can be seen as an 'innovation factory' containing multiple assets at different stages of development,” said Timothy Dixon, co-inventor, President, and CEO of the Company. “We believe that spinning off separate companies allows for hyper-accelerated development of the various technologies in our pipeline. We are confident that Res Nova Bio, Inc., will commercialize this radically new approach to cancer that combines the two most promising treatment approaches, suppression of angiogenesis and immunotherapy.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions files patent for stem cell-based cancer vaccine (scienceboard.net)
2 Therapeutic Solutions inks MOU with immunotherapy company Eutilogics | Seeking Alpha

View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005562/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International

FAQ

What is the purpose of the new spin-off company Res Nova Bio, Inc. related to TSOI?

Res Nova Bio, Inc. is created to develop the StemVacs-V anti-angiogenesis immunotherapy aimed at treating breast cancer.

What technology is Res Nova Bio, Inc. licensing from TSOI?

Res Nova Bio is licensing the StemVacs-V technology, which uses pluripotent stem cells to generate therapeutic vaccines targeting tumor blood vessels.

How does StemVacs-V work in cancer treatment?

StemVacs-V stimulates the immune system to attack and kill tumor blood vessel cells, leading to a significant reduction in tumor cells.

What are the expected benefits of using iPSC technology in StemVacs-V?

Using iPSC technology allows for standardized production of doses and potential gene editing, enhancing the therapeutic efficacy of the treatment.

What market opportunities does TSOI see with the launch of Res Nova Bio?

TSOI believes that spinning off Res Nova Bio will accelerate the development of their technologies and capitalize on innovative cancer treatment methods.